Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

Abstract

Background. In cancer patients, reduced serum albumin has been described as a marker for global declining health and poor prognosis. Our aim was to investigate the association of albumin concentrations with the occurrence of venous thromboembolism (VTE) and mortality in patients with cancer. Methods. This investigation was performed in the framework of the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study. We included 1,070 patients with active cancer and assayed serum albumin from venous blood taken at study inclusion. Risk for occurrence of VTE was calculated in a proportional subdistribution hazard regression model with respect to competing risk of death and adjusted for cancer site, leukocyte count, estimated glomerular filtration rate, and cholinesterase.

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial

“…[5][6][7] The present analysis extends the previous findings and demonstrates that a hypoalbuminemic state identified at hospitalization was associated with a greater VTE risk through 77 days after adjusting for potential confounders, thromboprophylaxis provision, and biomarkers for fibrinolysis (ie, D-dimer) and inflammation (ie, CRP). [5][6][7] The present analysis extends the previous findings and demonstrates that a hypoalbuminemic state identified at hospitalization was associated with a greater VTE risk through 77 days after adjusting for potential confounders, thromboprophylaxis provision, and biomarkers for fibrinolysis (ie, D-dimer) and inflammation (ie, CRP).…”

“…3 Low albumin may also reflect inflammation, poor nutritional status, or underlying liver or kidney disease that adversely impacts the clinical outcome. [5][6][7][8] We now report the association of baseline plasma albumin with VTE among hospitalized medically ill patients randomized in the Acute Medically Ill VTE Prevention with Extended Duration Betrixaban (APEX) Trial. [5][6][7][8] We now report the association of baseline plasma albumin with VTE among hospitalized medically ill patients randomized in the Acute Medically Ill VTE Prevention with Extended Duration Betrixaban (APEX) Trial.…”

Serum creatinine and albumin predict sarcoma‐specific survival in patients with myofibroblastic and fibroblastic sarcomas

“…In general, creatinine levels are influenced by lower muscle mass, creatine kinase activity, glomerular filtration, and renal secretion . Some studies examined the effect of kidney function on inpatient mortality, but data on cancer patients are scarce . The current evidence in the literature does not show a causal association between creatinine levels and mortality in cancer patients, but there are some reasonable thoughts about the underlying pathomechanism.…”

“…Serum creatinine is a byproduct of muscle metabolism that is excreted by the kidneys and therefore a commonly used indicator of renal function. Albumin and creatinine as surrogate for nutrition, patient's performance status and kidney function in cancer patients are associated with survival although the pathological relations are not clearly understood yet . Recent data from liposarcoma patients identified elevated serum creatinine, low albumin, and a decreased albumin‐creatinine ratio (ACR) as negative prognostic factor with worse disease specific survival …”

Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores?

“…Low serum albumin and low BMI are frequent findings in patients with advanced malignancy, and can be considered as proxy variables for poor performance status and cancer-associated cachexia/anorexia [4,5]. A combination of these variables, such as the ALI, may lead to a more refined outcome prediction as compared to using these variables individually, although no study to date has provided support for this hypothesis in a statistically stringent fashion.…”